The latest market report published by Credence Research, Inc., the global learning disability treatment market was valued at US$ 17,418.0 million in 2018 and is expected to reach US$ 30,493.1 million by 2027, increasing by 6.5 per cent to CAGR from 2019 to 2027.
According to research findings of the American Psychiatrist Association (APA), more than 50 per cent of children with learning disabilities will never be diagnosed in their lifetime. Effective early screening increases the quality of life of a patient with learning disabilities. Government authorities worldwide are providing adequate financial assistance for the establishment of special schools and clinics to help children and adults suffering from ADHD, dyslexia, dyspraxia and other mental disabilities.
Browse the full report at “Learning Disability Treatment Market”
The Pharmacological Treatment Module comprises 80 per cent of the treatment prescribed by a psychiatrist worldwide for the treatment of children with ADHD and cognitive disabilities. Stimulants such as Ritalin, Focalin, etc. are prescribed to improve the functioning of the brain CNS by inhibiting the absorption of dopamine and norepinephrine. Non-stimulants are prescribed for patients with symptoms of anxiety and depression. Technological advancement in assistive technology in the development of software and applications related to CBT and occupational therapy that are used by teachers to help children with learning disabilities.
Dyslexia dominates the Learning Disability Treatment Market Indication segment. Twenty-five percent of patients with ADHD have symptoms of dyslexia, with a major problem associated with reading, writing and word recognition problems. Dyscalculia is commonly seen at a certain level in adolescent children. A comprehensive assessment test and critical assessment of the underlying language skills result in early diagnosis of dyslexia and intervention therapy. Attention deficit hyperactivity disorder (ADHD) has a global prevalence rate of 2.2% with a high incidence in the male population compared to the female population. Combinational therapy of pharmacological drugs and assistive technology comprising of cognitive behavioral therapy (CBT) is used for its treatment throughout the globe.
North America is the largest regional market for learning disability treatment holding a share of 32.5%. The chief parameters influencing its market growth are rising prevalence of ADHD and proactive government initiatives to promote awareness and treatment for children with learning disabilities. Europe has the second largest market share of 29% on account of rising prevalence of dyslexia among all age groups. Asia Pacific currently represents 18.5% market share and is keen to register fastest growth in the near future owing to the rampant growth in special schools to treat learning disability in children and significant rise in IT healthcare companies providing assistive technology equipped with occupation therapy and cognitive behavioral therapy modules.
IT-Healthcare in collaboration with pharmaceutical companies actively participating in the learning disability treatment market are CogniFit, Eli Lilly & Company, Forest Laboratories, Inc., IMSE, Novartis AG, Pfizer, Inc., Shire, Plc., Therapro, Inc., Tumble N’ Dots, Inc. and Texthelp Ltd.
Key Market Movements:
- Rising prevalence of ADHD worldwide
- Technological advancement in the assistive technology treatment modules such as occupational therapy and cognitive behavioral therapy to treat learning disability in children
- Excellent formulation and development of stimulant and non stimulant medicines to achieve excellent drug efficacy and minimal adverse effects
Report Scope by Segments
By Therapy Type
- Stimulant Medication
- Non Stimulant Medication
- Orton Gillingham Interventional Therapy
- Occupational Therapy
- Assistive Technology
By Indication Type
- Attention Deficit Hyperactivity Disorder (ADHD)
By Geography Segment
- North America (U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (Middle East & Africa, Latin America)